Janssen Alzheimer Immunotherapy Research & Development LLC
Retrieval of Patient Information After Discontinuation
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2015-09-02
- Target Recruit Count
- 169
- Registration Number
- NCT01658722
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Interventions
- Biological: ACC-001 (vanutide cridificar)
- First Posted Date
- 2011-01-27
- Last Posted Date
- 2015-01-05
- Target Recruit Count
- 126
- Registration Number
- NCT01284387
- Locations
- 🇺🇸
Janssen AI Investigational Site, Oklahoma City, Oklahoma, United States
Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2010-12-07
- Last Posted Date
- 2014-05-09
- Target Recruit Count
- 146
- Registration Number
- NCT01254773
- Locations
- 🇺🇸
Janssen AI Investigational Site, Providence, Rhode Island, United States
A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2013-12-20
- Target Recruit Count
- 896
- Registration Number
- NCT00937352
- Locations
- 🇺🇸
Melbourne Internal Medicine Associates, Melbourne, Florida, United States
🇺🇸Four Rivers Clinical Research, Inc., Paducah, Kentucky, United States
🇺🇸Penn Memory Center, Philadelphia, Pennsylvania, United States
AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2008-02-04
- Last Posted Date
- 2013-11-25
- Target Recruit Count
- 194
- Registration Number
- NCT00606476
- Locations
- 🇺🇸
Janssen AI Investigational Site, Seattle, Washington, United States
Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2013-11-25
- Target Recruit Count
- 1121
- Registration Number
- NCT00575055
- Locations
- 🇺🇸
Research Center for Clinical Studies, Inc, Norwalk, Connecticut, United States
🇺🇸The Roskamp Institute, Inc, Sarasota, Florida, United States
🇺🇸Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, United States
Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2013-11-25
- Target Recruit Count
- 1331
- Registration Number
- NCT00574132
- Locations
- 🇺🇸
Neurostudies, Inc, Port Charlotte, Florida, United States
🇺🇸Princeton Medical Institute, Princeton, New Jersey, United States
🇺🇸Drexel University College of Medicine, Philadelphia, Pennsylvania, United States
AAB-001 in Patients With Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2005-05-30
- Last Posted Date
- 2012-03-14
- Target Recruit Count
- 234
- Registration Number
- NCT00112073
- Locations
- 🇺🇸
Brain Matters Research, Inc., Delray Beach, Florida, United States
🇺🇸Rush Presbyterian St. Luke's Medical Center, Chicago, Illinois, United States
🇺🇸Behavioral Neurology, Boston, Massachusetts, United States
Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- First Posted Date
- 2001-08-06
- Last Posted Date
- 2009-09-24
- Target Recruit Count
- 375
- Registration Number
- NCT00021723
- Locations
- 🇺🇸
Pivotal Research Centers, Peoria, Arizona, United States
🇺🇸21st Century Neurology, Phoenix, Arizona, United States
🇺🇸Pharmacology Research Institute, Northridge, California, United States